# US 2015/0105422 A1 · Salts and solvates of a tetrahydroisoquinoline derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105422 A1
- Document ID: US20150105422A1
- Status: Published application
- Kind: A1
- Application number: 14/573,774
- Filed: 2014-12-17
- Published: 2015-04-16
- Earliest claimed: 2010-07-21
- Assignees: Spinifex Pharmaceuticals Pty Ltd
- Applicants: Spinifex Pharmaceuticals, Pty Ltd
- Inventors: Thomas David McCarthy; Craig James Stewart Boyle; Alexander Redvers Eberlin; Peter Michael Kelly
- Web page: https://patentgrep.com/patent/US20150105422A1

## CPC

- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A61K 31/47: Quinolines; Isoquinolines
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

(S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.

## Claims

### Claim 1

The sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid.

### Claim 2 (depends on 1)

The sodium salt according to claim 1 in amorphous form.

### Claim 3

(S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form.

### Claim 4

A pharmaceutical composition comprising the sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid together with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4 wherein the sodium salt of (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid is in amorphous form.

### Claim 6

A pharmaceutical composition comprising (S)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form together with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 7 (depends on 4)

The pharmaceutical composition of claim 4 formulated for oral delivery.

### Claim 8 (depends on 5)

The pharmaceutical composition of claim 5 formulated for oral delivery.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6 formulated for oral delivery.

### Claim 10 (depends on 3)

The compound of claim 3 wherein the enantiomeric purity is >97% ee.

### Claim 11 (depends on 3)

The compound of claim 3 wherein the chemical purity is >96%.

### Claim 12 (depends on 2)

The compound of claim 2 wherein said amorphous form exhibits a solid state 13C NMR spectrum comprising peaks at about 55.2, 109.8, 128.4, and 151.7 ppm.

### Claim 13 (depends on 2)

The compound of claim 2 wherein said amorphous form exhibits a solid state 13C NMR spectrum substantially the same as FIG. 6.

### Claim 14 (depends on 2)

The compound of claim 2 wherein said amorphous form exhibits a solid state 13C NMR spectrum comprising peaks at about 26.2, 29.8, 39.0, 41.9, 45.7, 55.2, 60.4, 73.6, 94.4, 109.8, 121.3, 128.4, 139.9, 145.0, 151.7, 172.2, 175.7, and 178.8 ppm.
